- 國際領袖基金會 - 2017暑期公共事務實習受理報名
- ILF 國際領袖基金會
- 牛頓台灣日 5/6 新英格蘭台商會交流4/27 講座4/29 美食 5/21 高球賽5/27 教中文策略講座 7/8-20
- 校友、同學會 - 女神來了 4/28 華中科大5/2 北大年會5/7 清華校友 龍舟賽招兵買馬
- Cafe Philo - TAP Ian So 4/27 葉丙成座談4/29 死刑爭議4/30 夏星講座4/29
- 招聘 - Hopkinton school district
- 崇德佛院 普賢講堂 慈濟4/29
- 麻州州長動態 - Presents Green Communities Designation Awards
- 牛頓市議員馬惠美- 今年角逐牛頓市長
- 劍橋市議員張禮能 - Cambridge Mini Bond Program
- 羅德島州克蘭斯頓市長馮偉傑 Installs New Flood Warning System
- Plays -Peerless 4/27-5/27 Sinners 3/23-4/2 - Franklin 3/23-4/2 Every Piece of Me 4/20-30
- 台灣工程師的矽谷故事 失敗創業家書單 - 撕裂台灣社會
- 作者專欄： 王世輝 - 紅幫裁縫的傳奇
- 朱学渊 - 陈建奇、郭晓敏：特朗普重塑全球的三大战略
- 李保華忠告年輕人 做個遠大的夢
- 【你的學歷，能幫助公司什麼…？】如果沒有這 7 個特質，你讀到台大也沒用！
- 波士頓市議會議長吳弭 (Michelle Wu ) - open ed with Dukakis
- Harvard China Forum 4/21-23
- MIPIM 2017 - Real Estate Tech Trends from MIPIM
- 北美華文作協 5/13
- HCSSA - 漫談海龜中國科技創業大潮 4/28
- MIT ENERGY CLUB Mass Innovation Nights
- 博物館 - Guggenheim, Harvard Art, Forbes House, China Institute
- NECINA - NEW 5.0 Start up pitch 5/11
- 創業 - MIT-CHIEF HMS-CSSA華人創業論壇 燎原 5/9
- "緬因地" ˋ4/30
- AAC TAP CACAB NAAAP AARW AAWPI ASPIRE AWH WANG YMCA QARI
- 波士頓華埠社區中心/華美福利會/華埠社區聯盟/ 華人醫務中心/ 亞美社區發展協會/ 華夏文化協會
- CYPN 第三屆健身賽4/29 亞洲女性聯合會
- City of Boston, Quincy, Malden, Greenway 昆市市長亞裔顧問委員會
- 音樂 - 劍橋合唱團4/30 Parker 四重奏4/30 Eric Lu 5/13 古箏樂團 5...
- BCIC - 中美路演日 5/5
- 醫藥 - CABA 10 週年5/6 中国在研药品的FDA法规注册之路
星期三, 4月 19, 2017
感兴趣的同学请于4月26号前将创业项目简介 (300-500字，或slides) 发送至 CSSA@HMS-CSSA.ORG
：Folkman Auditorium, Enders Building, Children’s Hospital Boston
320 Longwood Ave, Boston, MA 02155
Tus-holdings （启迪控股）; Yongjin Group （涌金集团）；Legend Capital （君联资本）；CSC Group （中科招商）；Wuxi Healthcare Venture （毓承资本）；Simcere（先声药业）；GeneChem（吉凯基因）等等
Yide Alan Jiang oversees global market positioning and strategy development at XtalPi. Dr.Jiang has 14 years of experience in biopharmaceutical R&D, with expertise in managing external translational science collaborations between academia, industry and contract research organizations. Prior to joining XtalPi, Dr. Jiang held the role of Director of Asia R&D strategy and Associate Scientific Director at Genzyme, where he led cross-functional R&D collaborations and projects in Asia and conducted external consultation for various companies on R&D strategy and processes. His completed his postdoctoral fellowship of hematology and oncology at Harvard Medical School, and has worked as project manager at China’s National Institute for the Control of Pharmaceutical and Biological Products (NICPBP, NIFDC), CFDA.
Dr. Jiang earned his Ph.D. in molecular biology from University of Tennessee-Health Science Center and M.D. from Shanghai Medical University (now Shanghai Medical College of Fudan University).
Dr. Xiaoyu Tian joined VcanBio Center for Translational Biotechnology Co. in 2017 as Vice President, Product Development and is responsible for advancing all in-house and partnered drug development programs. With more than 20 years experiences in drug discovery and development at both academic and industrial settings, Dr. Tian is a technical expert in the molecular/structural biophysics-guided drug discovery and nanoparticle design for targeted drug delivery. He was formerly a senior research investigator at Bristol-Myer-Squibb, where he contributed to anti-viral and immune-oncology programs. Dr. Tian was a serial entrepreneur in the development of a pipeline of medical imaging diagnostics/devices, and the concurrent development of therapeutical products. He served as co-founder and R&D director of Beijing Beilu Pharmaceuticals, co-founder and President of Essenix Pharmaceuticals and cofounder and President of ADetect Diagnostics. He has been a senior consultant to HitGen Ltd and involved in early work at BioHermes Technologies on the DEL and IVD technologies for pharmaceutical applications. He is also an adjunct faculty member at Center for Drug Discovery, Northeastern University, where he contributes to explore the science of medicinal implications of Cannabis and the function of human endocannabinoid system. He received his Ph.D. in Pharmaceutical Sciences from the University of Connecticut, his BS and MS degrees in Quantum Electronics from Peking University, and a NIH post-doctoral fellowship on drug abuse.
(Jeff is also among those drafted the ground breaking CRISPR/Cas9 gene editing patent.)
Jeff Clark, M.D., J.D. is an associate at DLA Piper with a focus on patent litigation and the defense of pharmaceutical, life science and medical device companies in a variety of cases, including multi-district product liability litigation. Jeff also concentrates his practice on all aspects of patent law including patent prosecution and strategic counseling for life science start-ups, biotech, medical device and pharmaceutical companies. Jeff has extensive clinical and basic science research experience. He was a clinical research fellow in the Molecular and Vascular Medicine Unit, Renal Division (Department of Medicine), at Beth Israel Deaconess Medical Center and in the Cardiovascular Research Center (Department of Cardiology) at Massachusetts General Hospital. Jeff has authored and co-authored several publications in peer-reviewed journals and has presented at the national American Society of Nephrology Renal Week conference.
Chesley Chen is Chief Executive Officer of Safety Partners, Inc., which provides environmental, health, and safety programs to over 200 life science and technology companies each year. Chen is a serial entrepreneur and brings extensive experience in launching and scaling up early to mid-stage health technology, life science, and financial service ventures. He has over 30 years experience in executive management, corporate strategy, client service, product development, operations, technology, and finance. He has worked for a wide range of firms including Health Dialog, Good Measures, The Warner Babcock Institute for Green Chemistry, and Goldman Sachs.
Chen holds a BS in Civil Engineering from Tufts University, an SM in Aeronautics and Astronautics from MIT, and an MBA from the Harvard Business School. As he continues on his career journey, he dedicates time to sharing his experiences about his path to CEO and his ongoing learnings. Outside of work, he devotes his time to family, rock climbing, martial arts, piano, and studying the arts and sciences. He is of Chinese heritage, the son and grandson of Chinese immigrants.
Han-kai Yi joined TusPark (Jiangsu) as Vice General Manager in 2014. He oversees the operation, corporate relationship, corporate innovation service and incubation departments for TusParks the Jiangsu, Anhui and Zhejiang provinces, as well as the Qingpu district of Shanghai. Mr Yi has over 10 years experience developing science and technology service facilities. He is an alumnus of Nanjing University